Overview

Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Prospective, unmasked, randomized evaluation of the iStent in patients with primary open-angle glaucoma. Patients will be randomized to one of two groups: 1) iStent, or 2) medication.
Phase:
Phase 4
Details
Lead Sponsor:
Glaukos Corporation
Treatments:
Antihypertensive Agents
Latanoprost
Timolol